Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 15
2000 54
2001 47
2002 64
2003 71
2004 70
2005 71
2006 70
2007 53
2008 72
2009 68
2010 55
2011 97
2012 108
2013 134
2014 118
2015 147
2016 193
2017 236
2018 256
2019 218
2020 281
2021 274
2022 205
2023 187
2024 206
2025 232
2026 165

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,856 results

Results by year

Filters applied: . Clear all
Page 1
Lung Cancer in Women: The Past, Present, and Future.
Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, Franco I, Odai-Afotey A, Meza K, Swami N, Patel J, Sequist LV. Florez N, et al. Clin Lung Cancer. 2024 Jan;25(1):1-8. doi: 10.1016/j.cllc.2023.10.007. Epub 2023 Oct 20. Clin Lung Cancer. 2024. PMID: 37940410 Free article. Review.
Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles.
Malik PS, Pathak N, Sharma A, Birla M, Rastogi A, Sharma A, Khurana S, Pushpam D, Gupta I, Rathore A, Jain D, Kumar S, Pathy S, Kaushal R, Noronha V, Prabhash K, Karaba A, Gauribidanur Raghavendrachar V, Muniyappa N. Malik PS, et al. Clin Lung Cancer. 2025 Jul;26(5):420-428.e4. doi: 10.1016/j.cllc.2025.02.014. Epub 2025 Feb 22. Clin Lung Cancer. 2025. PMID: 40122770
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Bronstein A, Curcio H, Monnet I, Ricordel C, Bigay-Game L, Geier M, Decroisette C, Daniel C, Guisier F, Swalduz A, Toffart AC, Doubre H, Peloni JM, Arpin D, Morel H, Veillon R, Clarisse B, Chouaïd C, Greillier L, Bylicki O; GFPC. Bronstein A, et al. Clin Lung Cancer. 2025 Dec;26(8):e724-e730. doi: 10.1016/j.cllc.2025.08.009. Epub 2025 Aug 21. Clin Lung Cancer. 2025. PMID: 40947344 Free article.
2,856 results